We have recently demonstrated that PRG4, upon binding to CD44, interferes with the capacity of this receptor to mediate resistance to sorafenib and regorafenib, both drugs employed as HCC treatment options [53]. The gene discussed is PRG4; the disease is hepatocellular carcinoma.